Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper
References
- Carmel S. Health and well-being in late life: gender differences worldwide. Front Med. 2019 Oct 10;6:218. DOI: 10.3389/fmed.2019.00218
- Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Postmenopausal hormone therapy and mortality. N Engl J Med. 1997;336(25):1769–1775. DOI: 10.1056/NEJM199706193362501
- Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279(9):688–695. DOI: 10.1001/jama.279.9.688
- Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20(1):47–63. DOI: 10.1016/0091-7435(91)90006-P
- Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117(12):1016–1037. DOI: 10.7326/0003-4819-117-12-1016
- American College of Physicians. Guidelines for counseling postmenopausal women about preventive hormone therapy. Ann Intern Med. 1992;117(12):1038–1041. DOI: 10.7326/0003-4819-117-12-1038
- Mehta JM, Chester RC, Kling JM. The timing hypothesis: hormone therapy for treating symptomatic women during menopause and its relationship to cardiovascular disease. J Womens Health. 2019;28(5):705–711. DOI: 10.1089/jwh.2018.7201
- Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res. 2009;2(3):228–239. DOI: 10.1007/s12265-009-9104-y
- Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, Stanczyk FZ, Selzer RH, Azen SP; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221–1231. DOI: 10.1056/NEJMoa1505241
- Genazzani AR, Divakar H, Khadilkar SS, Monteleone P, Evangelisti B, Galal AF, Priego PIR, Simoncini T, Giannini A, Goba G, Benedetto C. Counseling in menopausal women: How to address the benefits and risks of menopause hormone therapy. A FIGO position paper. Int J Gynecol Obstet. 2024;164(2):516–530. DOI: 10.1002/ijgo.15278
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333. DOI: 10.1001/jama.288.3.321
- Machens K, Schmidt-Gollwitzer K. Issues to debate on the Women’s Health Initiative (WHI) study. Hormone replacement therapy: an epidemiological dilemma? Hum Reprod. 2003;18(10):1992–1999. DOI: 10.1093/humrep/deg406
- Klaiber EL, Vogel W, Rako S. A critique of the Women’s Health Initiative hormone therapy study. Fertil Steril. 2005;84(6):1589–1601. DOI: 10.1016/j.fertnstert.2005.08.010
- Clark JH. A critique of Women’s Health Initiative studies (2002–2006). Nucl Recept Signal. 2006;4:
e023 . - Goldman JA. The Women’s Health Initiative 2004: review and critique. MedGenMed. 2004;6(3):65.
- Piantadosi S. Larger lessons from the Women’s Health Initiative. Epidemiology. 2003;14(1):6–7. DOI: 10.1097/00001648-200301000-00004
- McDonough PG. The randomized world is not without its imperfections: reflections on the Women’s Health Initiative study. Fertil Steril. 2002;78(5):951–956. DOI: 10.1016/S0015-0282(02)04403-5
- Lacey JV
Jr . The WHI ten years later: an epidemiologist’s view. J Steroid Biochem Mol Biol. 2014;142:12–15. DOI: 10.1016/j.jsbmb.2013.08.006 - Stute P, Marsden J, Salih N, Cagnacci A. Reappraising 21 years of the WHI study: putting the findings in context for clinical practice. Maturitas. 2023;174:8–13. DOI: 10.1016/j.maturitas.2023.04.271
- Thiriet M. Cardiovascular Disease: An Introduction. Vasculopathies. 2019 Feb 19;8:1–90. DOI: 10.1007/978-3-319-89315-0_1
- Global Burden of Disease Study; Institute for Health Metrics and Evaluation. Global Health Data Exchange [Internet]. Seattle (WA): IHME; Available from:
https://ghdx.healthdata.org - Tunc E, Eve AA, Madak-Erdogan Z. Coronary microvascular dysfunction and estrogen receptor signaling. Trends Endocrinol Metab. 2020 Mar;31(3):228–238. DOI: 10.1016/j.tem.2019.11.001
- Smilowitz NR, Mahajan AM, Roe MT, Hellkamp AS, Chiswell K, Gulati M, Reynolds HR. Mortality of myocardial infarction by sex, age, and obstructive coronary artery disease status in the ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With the Guidelines). Circ Cardiovasc Qual Outcomes. 2017 Dec;10(12):
e003443 . DOI: 10.1161/CIRCOUTCOMES.116.003443 - McSweeney JC, Rosenfeld AG, Abel WM, Braun LT, Burke LE, Daugherty SL, Fletcher GF, Gulati M, Mehta LS, Pettey C, Reckelhoff JF; American Heart Association Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, Council on Hypertension, Council on Lifestyle and Cardiometabolic Health, and Council on Quality of Care and Outcomes Research. Preventing and experiencing ischemic heart disease as a woman: State of the science: A scientific statement from the American Heart Association. Circulation. 2016;133(13):1302–1331. DOI: 10.1161/CIR.0000000000000381
- Stehli J, Martin C, Brennan A, Dinh DT, Lefkovits J, Zaman S. Sex Differences Persist in Time to Presentation, Revascularization, and Mortality in Myocardial Infarction Treated With Percutaneous Coronary Intervention. J Am Heart Assoc. 2019 May 21;8(10):
e012161 . DOI: 10.1161/JAHA.119.012161 - Kenkre TS, Malhotra P, Johnson BD, Handberg EM, Thompson DV, Marroquin OC, Rogers WJ, Pepine CJ, Bairey Merz CN, Kelsey SF. Ten-year mortality in the WISE Study (Women’s Ischemia Syndrome Evaluation). Circ Cardiovasc Qual Outcomes. 2017;10(12):
e003863 . DOI: 10.1161/CIRCOUTCOMES.116.003863 - Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson CO, LeGrand KE, Mensah GA, Razo C, Stark B, Varieur Turco J, Roth GA. Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990–2021. J Am Coll Cardiol. 2022 Dec 20;80(25):2372–2425. DOI: 10.1016/j.jacc.2022.11.001
- Mahalleh M, Narimani-Javid R, Izadpanahi K, Eshraghi R, Behboodi K, Afzalian A, Hashempoor A, Thachil R, May H, Waheed A, Aronow WS, Soleimani H, Hosseini K. Hearts apart: exploring sex disparity in the global and regional burden of ischemic heart disease; a systematic analysis from the global burden of disease study 1990–2021. BMC Cardiovasc Disord. 2025 May 2;25(1):346. DOI: 10.1186/s12872-025-04770-0
- Cheng Q, Zhou S, Zhong H, Wang Z, Liu C, Sun J, Deng J. Global, regional, and national burden and risk factors of ischemic heart disease, 1990–2021: an analysis of the global burden of disease study. Front Public Health. 2025 Apr 25;13:1563631. DOI: 10.3389/fpubh.2025.1563631
- Cushman M, Shay CM, Howard VJ, Jiménez MC, Lewey J, McSweeny JC, Newby LK, Poudel R, Reynolds HR, Rexrode KM, Sims M, Mosca LJ. Ten-year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association National Survey: a special report from the American Heart Association. Circulation. 2021 Feb 16;143(7):e239–248. DOI: 10.1161/CIR.0000000000000907
- Xiang D, Liu Y, Zhou S, Zhou E, Wang Y. Protective effects of estrogen on cardiovascular disease mediated by oxidative stress. Oxid Med Cell Longev. 2021 Jun 28;2021:5523516. DOI: 10.1155/2021/5523516
- Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017 Oct 24;8(1):33. DOI: 10.1186/s13293-017-0152-8
- Beazer JD, Freeman DJ. Estradiol and HDL function in women – a partnership for life. J Clin Endocrinol Metab. 2022 Apr 19;107(5):e2192–e2194. DOI: 10.1210/clinem/dgab811
- El Khoudary SR, Nasr A, Billheimer J, Brooks MM, McConnell D, Crawford S, Orchard TJ, Rader DJ, Matthews KA. Associations of endogenous hormones with HDL novel metrics across the menopause transition: the SWAN HDL study. J Clin Endocrinol Metab. 2022 Jan 1;107(1):e303–e314. DOI: 10.1210/clinem/dgab595
- Luo F, Guo Y, Ruan GY, Peng R, Li XP. Estrogen lowers triglyceride via regulating hepatic APOA5 expression. Lipids Health Dis. 2017;16(1):72. DOI: 10.1186/s12944-017-0463-0
- van Oortmerssen JAE, Mulder JWCM, Kavousi M, Roeters van Lennep JE. Lipid metabolism in women: a review. Atherosclerosis. 2025;405:119213. DOI: 10.1016/j.atherosclerosis.2025.119213
- Ventura-Clapier R, Piquereau J, Veksler V, Garnier A. Estrogens, Estrogen Receptors Effects on Cardiac and Skeletal Muscle Mitochondria. Front Endocrinol. 2019 Aug 14;10:557. DOI: 10.3389/fendo.2019.00557
- Rattanasopa C, Phungphong S, Wattanapermpool J, Bupha-Intr T. Significant role of estrogen in maintaining cardiac mitochondrial functions. J Steroid Biochem Mol Biol. 2015 Mar;147:1–9. DOI: 10.1016/j.jsbmb.2014.11.009
- Klinge CM. Estrogenic control of mitochondrial function. Redox Biol. 2020 Apr;31:101435. DOI: 10.1016/j.redox.2020.101435
- Murugasamy K, Munjal A, Sundaresan NR. Emerging roles of SIRT3 in cardiac metabolism. Front Cardiovasc Med. 2022 Mar 18;9:850340. DOI: 10.3389/fcvm.2022.850340
- Jia K, Luo X, Yi J, Zhang C. Hormonal influence: unraveling the impact of sex hormones on vascular smooth muscle cells. Biol Res. 2024 Sep 4;57(1):61. DOI: 10.1186/s40659-024-00542-w
- Osako MK, Nakagami H, Koibuchi N, Shimizu H, Nakagami F, Koriyama H, Shimamura M, Miyake T, Rakugi H, Morishita R. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ Res. 2010 Aug 20;107(4):466–475. DOI: 10.1161/CIRCRESAHA.110.216846
- Barnabas O, Wang H, Gao XM. Role of estrogen in angiogenesis in cardiovascular diseases. J Geriatr Cardiol. 2013 Dec;10(4):377–382. DOI: 10.3969/j.issn.1671-5411.2013.04.008
- Gersh FL, O’Keefe JH, Lavie CJ, Henry BM. The renin–angiotensin–aldosterone system in postmenopausal women: the promise of hormone therapy. Mayo Clin Proc. 2021 Dec;96(12):3130–3141. DOI: 10.1016/j.mayocp.2021.08.009
- Alvord VM, Kantra EJ, Pendergast JS. Estrogens and the circadian system. Semin Cell Dev Biol. 2022 Jun;126:56–65. DOI: 10.1016/j.semcdb.2021.04.010
- Thosar SS, Butler MP, Shea SA. Role of the circadian system in cardiovascular disease. J Clin Invest. 2018 Jun 1;128(6):2157–2167. DOI: 10.1172/JCI80590
- Coutinho T, Mielniczuk LM, Srivaratharajah K, deKemp R, Wells GA, Beanlands RS. Coronary artery microvascular dysfunction: Role of sex and arterial load. Int J Cardiol. 2018 Nov 1;270:42–47. DOI: 10.1016/j.ijcard.2018.06.072
- Kim SR, Kim MN, Cho DH, Kim HD, Bae SA, Kim HL, Kim MA, Hong KS, Shim WJ, Park SM. Sex differences of sequential changes in coronary blood flow and microvascular function in patients with suspected angina. Clin Res Cardiol. 2024 Dec;113(12):1638–1649. DOI: 10.1007/s00392-023-02358-2
- Maas AHEM, Rosano G, Cifkova R, Chieffo A, van Dijken D, Hamoda H, Kunadian V, Laan E, Lambrinoudaki I, Maclaran K, Panay N, Stevenson JC, van Trotsenburg M, Collins P. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J. 2021 Mar 7;42(10):967–984. Erratum in: Eur Heart J. 2022 Jul 1;43(25):2372. DOI: 10.1093/eurheartj/ehaa1044
- Riascos-Bernal DF, Quinones G, Abdelaal SA, Menegus MA, Sibinga NES. Pathogenesis of plaque erosion. Trends Cardiovasc Med 2025 Sep 9:36(2):105–112. DOI: 10.1016/j.tcm.2025.09.004
- Yahagi K, Davis HR, Arbustini E, Virmani R. Sex differences in coronary artery disease: pathological observations. Atherosclerosis 2015;239:260–267. DOI: 10.1016/j.atherosclerosis.2015.01.017
- Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, Banning AP, Budaj A, Buechel RR, Chiariello GA, Chieffo A, Christodorescu RM, Deaton C, Doenst T, Jones HW, Kunadian V, Mehilli J, Milojevic M, Piek JJ, Pugliese F, Rubboli A, Semb AG, Senior R, Ten Berg JM, Van Belle E, Van Craenenbroeck EM, Vidal-Perez R, Winther S; ESC Scientific Document Group. 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024 Sep 29;45(36):3415–3537. Erratum in: Eur Heart J. 2025 Apr 22;46(16):1565. DOI: 10.1093/eurheartj/ehae177
- Nasir K, Budoff MJ, Wong ND, Scheuner M, Herrington D, Arnett DK, Szklo M, Greenland P, Blumenthal RS. Family history of premature coronary heart disease and coronary artery calcification: Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2007;116:619–626. DOI: 10.1161/CIRCULATIONAHA.107.688739
- Chacko M, Sarma PS, Harikrishnan S, Zachariah G, Jeemon P. Family history of cardiovascular disease and risk of premature coronary heart disease: a matched case-control study. Wellcome Open Res 2020;5:70. DOI: 10.12688/wellcomeopenres.15829.2
- Andreotti F, Crea F, Patti G, Shoulders CC, Navarese EP, Robishaw J, Maseri A, Hennekens CH. Family history in first degree relatives of patients with premature cardiovascular disease. Int J Cardiol 2021;333:215–218. DOI: 10.1016/j.ijcard.2021.03.026
- Razavi AC, Bhatia HS, Dardari ZA, Mehta A, Nasir K, Blankstein R, Isiadinso I, Quyyumi AA, Vaccarino V, Fialkow JA, Khoury MJ, Coronado F, Budoff MJ, Blumenthal RS, Whelton SP, Mortensen MB, Sperling LS, Matsushita K, Blaha MJ, Dzaye O. Family history of premature atherosclerotic cardiovascular disease and lipoprotein(a) levels: a multi cohort analysis. Eur J Prev Cardiol 2025 Jul 8:33(3):443–445. DOI: 10.1093/eurjpc/zwaf392
- Yeo WJ, Abraham R, Surapaneni AL, Schlosser P, Ballew SH, Ozkan B, Flaherty CM, Yu B, Bonventre JV, Parikh CR, Kimmel PL, Vasan RS, Coresh J, Grams ME. Sex differences in hypertension and its management throughout life. Hypertension. 2024 Nov;81(11):2263–2274. DOI: 10.1161/HYPERTENSIONAHA.124.22980
- Ji H, Kim A, Ebinger JE, Niiranen TJ, Claggett BL, Bairey Merz CN, Cheng S. Sex differences in blood pressure trajectories over the life course. JAMA Cardiol. 2020 Mar 1;5(3):19–26. Erratum in: JAMA Cardiol. 2020 Mar 1;5(3):364. DOI: 10.1001/jamacardio.2019.5306
- Gerdts E, Sudano I, Brouwers S, Borghi C, Bruno RM, Ceconi C, Cornelissen V, Diévart F, Ferrini M, Kahan T, Løchen ML, Maas AHEM, Mahfoud F, Mihailidou AS, Moholdt T, Parati G, de Simone G. Sex differences in arterial hypertension. Eur Heart J. 2022 Dec 7;43(46):4777–4788. DOI: 10.1093/eurheartj/ehac470
- Cameron NA, Blyler CA, Bello NA. Oral contraceptive pills and hypertension: a review of current evidence and recommendations. Hypertension. 2023;80(5):924–935. DOI: 10.1161/HYPERTENSIONAHA.122.20018
- Kalenga CZ, Dumanski SM, Metcalfe A, Robert M, Nerenberg KA, MacRae JM, Premji Z, Ahmed SB. The effect of non-oral hormonal contraceptives on hypertension and blood pressure: A systematic review and meta-analysis. Physiol Rep. 2022 May;10(9):
e15267 . DOI: 10.14814/phy2.15267 - Stanczyk FZ, Winer SA, Foidart JM, Archer DF. Comparison of estrogenic components used for hormonal contraception. Contraception. 2024;130:110310. DOI: 10.1016/j.contraception.2023.110310
- Kimble T, Burke AE, Barnhart KT, Archer DF, Colli E, Westhoff CL. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen. Contracept X. 2020;2:100020. DOI: 10.1016/j.conx.2020.100020
- Liu H, Yao J, Wang W, Zhang D. Association between duration of oral contraceptive use and risk of hypertension: A meta-analysis. J Clin Hypertens (Greenwich). 2017 Oct;19(10):1032–1041. DOI: 10.1111/jch.13042
- Raparelli V, Morano S, Franconi F, Lenzi A, Basili S. Sex differences in type 2 diabetes: implications for cardiovascular risk management. Curr Pharm Des. 2017;23(10):1471–1476. DOI: 10.2174/1381612823666170130153704
- Regensteiner JG, Reusch JEB. Sex differences in cardiovascular consequences of hypertension, obesity, and diabetes: JACC Focus Seminar 4/7. J Am Coll Cardiol. 2022 Apr 19;79(15):1492–1505. DOI: 10.1016/j.jacc.2022.02.010
- Matuleviciene-Anängen V, Rosengren A, Svensson AM, Pivodic A, Gudbjörnsdottir S, Wedel H, Kosiborod M, Haraldsson B, Lind M. Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes. Heart. 2017 Nov;103(21):1687–1695. DOI: 10.1136/heartjnl-2016-311050
- Huxley RR, Peters SA, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Mar;3(3):198–206. DOI: 10.1016/S2213-8587(14)70248-7
- Rawshani A, Sattar N, Franzén S, Rawshani A, Hattersley AT, Svensson AM, Eliasson B, Gudbjörnsdottir S. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018 Aug 11;392(10146):477–486. DOI: 10.1016/S0140-6736(18)31506-X
- Dei Cas A, Aldigeri R, Mantovani A, Masulli M, Palmisano L, Cavalot F, Bonomo K, Baroni MG, Cossu E, Cavallo G, Cimini FA, Buzzetti R, Mignogna C, Leonetti F, Bacci S, Trevisan R, Morieri ML, Pollis RM, Targher G, Vigili de Kreutzenberg S. Sex differences in cardiovascular disease and cardiovascular risk estimation in patients with type 1 diabetes. J Clin Endocrinol Metab. 2023 Aug 18;108(9):e789–e798. DOI: 10.1210/clinem/dgad127
- Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants. BMJ. 2018 Nov 7;363:k4247. DOI: 10.1136/bmj.k4247
- Prospective Studies Collaboration, Asia Pacific Cohort Studies Collaboration. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980,793 adults from 68 prospective studies. Lancet Diabetes Endocrinol. 2018;6(7):538–546. DOI: 10.1016/S2213-8587(18)30079-2
- Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542–1551. DOI: 10.1007/s00125-014-3260-6
- Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Bansal N, Beaton AZ, Commodore-Mensah Y, Currie ME, Elkind MSV, Fan W, Generoso G, Gibbs BB, Heard DG, Hiremath S, Johansen MC, Kazi DS, Ko D, Leppert MH, Magnani JW, Michos ED, Mussolino ME, Parikh NI, Perman SM, Rezk-Hanna M, Roth GA, Shah NS, Springer MV, St-Onge MP, Thacker EL, Urbut SM, Van Spall HGC, Voeks JH, Whelton SP, Wong ND, Wong SS, Yaffe K, Palaniappan LP; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Committee. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025 Feb 25;151(8):e41–e660. DOI: 10.1161/CIR.0000000000001303
- van Oortmerssen JAE, Mulder JWCM, van der Bijl MF, Mijnster RJM, Kavousi M, Roeters van Lennep JE, IMPRESS consortium. Lipid lowering therapy utilization and lipid goal attainment in women. Curr Atheroscler Rep. 2025 Jan 28;27(1):29. DOI: 10.1007/s11883-025-01275-1
- Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, Palagashvilli T, Alam S, Mues KE, Bhatt DL, Kosiborod MN, GOULD Investigators. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060–1068. DOI: 10.1001/jamacardio.2021.1810
- Navar AM, Kolkailah AA, Gupta A, Gillard KK, Israel MK, Wang Y, Peterson ED. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322,153 patients. Circ Cardiovasc Qual Outcomes. 2023 Aug;16(8):533–543. DOI: 10.1161/CIRCOUTCOMES.122.009787
- Brown CJ, Chang LS, Hosomura N, Malmasi S, Morrison F, Shubina M, Lan Z, Turchin A. Assessment of sex disparities in nonacceptance of statin therapy and low-density lipoprotein cholesterol levels among patients at high cardiovascular risk. JAMA Netw Open. 2023;6(2):
e231047 . DOI: 10.1001/jamanetworkopen.2023.1047 - Inaraja V, Thuissard I, Andreu-Vazquez C, Jodar E. Lipid profile changes during the menopausal transition. Menopause. 2020 Jul;27(7):780–787. DOI: 10.1097/GME.0000000000001532
- El Khoudary SR, Chen X, Nasr AN, Billheimer J, Brooks MM, McConnell D, Orchard TJ, Crawford SL, Matthews KA, Rader DJ. HDL (high-density lipoprotein) subclasses, lipid content, and function trajectories across the menopause transition: SWAN-HDL study. Arterioscler Thromb Vasc Biol. 2021;41(2):951–961. DOI: 10.1161/ATVBAHA.120.315355
- Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, Dumanski SM, Gulati M, Hess CN, Holven KB, Kavousi M, Kayıkçıoğlu M, Lutgens E, Michos ED, Prescott E, Stock JK, Tybjaerg-Hansen A, Wermer MJH, Benn M. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157–4173. DOI: 10.1093/eurheartj/ehad472
- Anagnostis P, Antza C, Trakatelli C, Lambrinoudaki I, Goulis DG, Kotsis V. The effect of menopause on lipoprotein(a) concentrations: a systematic review and meta-analysis. Maturitas. 2023;167:39–45. DOI: 10.1016/j.maturitas.2022.09.012
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050. DOI: 10.1016/S0140-6736(23)02750-2
- Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, Solomon CG, Willett WC. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345(11):790–797. DOI: 10.1056/NEJMoa010492
- Li H, Konja D, Wang L, Wang Y. Sex differences in adiposity and cardiovascular diseases. Int J Mol Sci. 2022 Aug 19;23(16):9338. DOI: 10.3390/ijms23169338
- Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, Sutton-Tyrrell K. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? J Am Coll Cardiol. 2009 Dec 15;54(25):2366–2373. DOI: 10.1016/j.jacc.2009.10.009
- Yang Y, He L, Han S, Yang N, Liu Y, Wang X, Li Z, Ping F, Xu L, Li W, Zhang H, Li Y. Sex differences in the efficacy of glucagon-like peptide-1 receptor agonists for weight reduction: a systematic review and meta-analysis. J Diabetes. 2025;17(3):
e70063 . DOI: 10.1111/1753-0407.70063 - Piccini S, Favacchio G, Morenghi E, Mazziotti G, Lania AG, Mirani M. Real-world sex differences in type 2 diabetes patients treated with GLP-1 receptor agonists. Diabetes Res Clin Pract. 2024;212:111689. DOI: 10.1016/j.diabres.2024.111689
- Ji H, Sabanayagam C, Matsushita K, Cheng CY, Rim TH, Sheng B, Li H, Tham YC, Cheng S, Wong TY. Sex differences in cardiovascular-kidney-metabolic syndrome: 30-year US trends and mortality risks—brief report. Arterioscler Thromb Vasc Biol. 2025 Jan;45(1):157–161. DOI: 10.1161/ATVBAHA.124.321629
- Barrett PM, McCarthy FP, Kublickiene K, Cormican S, Judge C, Evans M, Kublickas M, Perry IJ, Stenvinkel P, Khashan AS. Adverse pregnancy outcomes and long-term maternal kidney disease: a systematic review and meta-analysis. JAMA Netw Open. 2020 Feb 5;3(2):
e1920964 . DOI: 10.1001/jamanetworkopen.2019.20964 - Ridker PM, Moorthy MV, Cook NR, Rifai N, Lee IM, Buring JE. Inflammation, cholesterol, lipoprotein(a), and 30-year cardiovascular outcomes in women. N Engl J Med. 2024 Dec 5;391(22):2087–2097. DOI: 10.1056/NEJMoa2405182
- Kraaijenhof JM, Nurmohamed NS, Nordestgaard AT, Reeskamp LF, Stroes ESG, Hovingh GK, Boekholdt SM, Ridker PM. Low-density lipoprotein cholesterol, C-reactive protein, and lipoprotein(a) universal one-time screening in primary prevention: the EPIC-Norfolk study. Eur Heart J. 2025 Apr 1:46(39):3875–3884. DOI: 10.1093/eurheartj/ehaf209
- Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, Mason JC, Rahimi K, McMurray JJV, Verbakel JY. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet. 2022 Sep 3;400(10354):733–743. DOI: 10.1016/S0140-6736(22)01349-6
- Moran CA, Collins LF, Beydoun N, Mehta PK, Fatade Y, Isiadinso I, Lewis TT, Weber B, Goldstein J, Ofotokun I, Quyyumi A, Choi MY, Titanji K, Lahiri CD. Cardiovascular implications of immune disorders in women. Circ Res. 2022 Feb 18;130(4):593–610. DOI: 10.1161/CIRCRESAHA.121.319877
- Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010 Sep;30(9):1065–1072. DOI: 10.1177/0333102409355601
- Peng KP, Chen YT, Fuh JL, Tang CH, Wang SJ. Migraine and incidence of ischemic stroke: a nationwide population-based study. Cephalalgia. 2017 Apr;37(4):327–335. DOI: 10.1177/0333102416642602
- Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH, Johannsson M, Thorgeirsson G, Launer L, Gudnason V. Migraine with aura and risk of cardiovascular and all cause mortality in men and women: prospective cohort study. BMJ. 2010 Aug 24;341:c3966. DOI: 10.1136/bmj.c3966
- Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett WC, Manson JE, Rexrode KM. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016 May 31;353:i2610. DOI: 10.1136/bmj.i2610
- Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB. Migraine and cardiovascular disease: a population-based study. Neurology. 2010 Feb 23;74(8):628–635. DOI: 10.1212/WNL.0b013e3181d0cc8b
- Adelborg K, Szépligeti SK, Holland-Bill L, Ehrenstein V, Horváth-Puhó E, Henderson VW, Sørensen HT. Migraine and risk of cardiovascular diseases: Danish population based matched cohort study. BMJ. 2018 Jan 31;360:k96. DOI: 10.1136/bmj.k96
- Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA. 2006 Jul 19;296(3):283–291. DOI: 10.1001/jama.296.3.283
- Lee ST, Chu K, Jung KH, Kim DH, Kim EH, Choe VN, Kim JH, Im WS, Kang L, Park JE, Park HJ, Park HK, Song EC, Lee SK, Kim M, Roh JK. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology. 2008 Apr 22;70(17):1510–1517. DOI: 10.1212/01.wnl.0000294329.93565.94
- Kovács K, Hermán F, Filep J, Jelencsik I, Magyar K, Csanda E. Platelet aggregation of migraineurs during and between attacks. Cephalalgia. 1990 Aug;10(4):161–165. DOI: 10.1046/j.1468-2982.1990.1004161.x
- D’Andrea G, Toldo M, Cortelazzo S, Milone FF. Platelet activity in migraine. Headache. 1982 Sep;22(5):207–212. DOI: 10.1111/j.1526-4610.1982.hed2205207.x
- Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769–779. DOI: 10.1016/S0140-6736(13)60900-9
- Bonnesen K, Fuglsang CH, Schmidt M. Impact of nonsteroidal anti-inflammatory drug use on the migraine-associated risk of myocardial infarction and ischemic stroke: a population-based cohort study. Neurology. 2024 Dec 24;103(12):
e210034 . DOI: 10.1212/WNL.0000000000210034 - St-Onge MP, Grandner MA, Brown D, Conroy MB, Jean-Louis G, Coons M, Bhatt DL; American Heart Association Obesity, Behavior Change, Diabetes, and Nutrition Committees of the Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health. Circulation. 2016;134(18):e367–386. DOI: 10.1161/CIR.0000000000000444
- Chen Y, Yu G, Zhang X, Cai Y, Hu T, Xue R. Gender-based differences in the association of self-reported sleep duration with cardiovascular disease and diabetes. BMC Public Health. 2024 Sep 27;24(1):2624. DOI: 10.1186/s12889-024-20126-3
- Jehan S, Masters-Isarilov A, Salifu I, Zizi F, Jean-Louis G, Pandi-Perumal SR, Gupta R, Brzezinski A, McFarlane SI. Sleep disorders in postmenopausal women. J Sleep Disord Ther. 2015;4(5):212.
- Pankowska MM, Lu H, Wheaton AG, Liu Y, Lee B, Greenlund KJ, Carlson SA. Prevalence and geographic patterns of self-reported short sleep duration among US adults, 2020. Prev Chronic Dis. 2023 Jun 29;20:
E53 . DOI: 10.5888/pcd20.220400 - DePree B, Shiozawa A, King D, Schild A, Zhou M, Yang H, Mancuso S. Association of menopausal vasomotor symptom severity with sleep and work impairments: a US survey. Menopause. 2023 Sep 1;30(9):887–897. DOI: 10.1097/GME.0000000000002237
- Prather AA, Epel ES, Cohen BE, Neylan TC, Whooley MA. Gender differences in the prospective associations of self-reported sleep quality with biomarkers of systemic inflammation and coagulation: findings from the Heart and Soul Study. J Psychiatr Res. 2013 Sep;47(9):1228–1235. DOI: 10.1016/j.jpsychires.2013.05.004
- Cowie MR, Linz D, Redline S, Somers VK, Simonds AK. Sleep disordered breathing and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol. 2021 Aug 10;78(6):608–624. DOI: 10.1016/j.jacc.2021.05.048
- Bonsignore MR, Saaresranta T, Riha RL. Sex differences in obstructive sleep apnoea. Eur Respir Rev. 2019 Nov 6;28(154):190030. DOI: 10.1183/16000617.0030-2019
- Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nuñez N, Caballero-Martinez I, Catalan-Serra P, Almeida-Gonzalez CV. Role of sleep apnea and continuous positive airway pressure therapy in the incidence of stroke or coronary heart disease in women. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1544–1550. DOI: 10.1164/rccm.201311-2012OC
- Palmer J, Lloyd A, Steele L, Fotheringham J, Teare D, Iqbal J, Grech ED. Differential risk of ST-segment elevation myocardial infarction in male and female smokers. J Am Coll Cardiol. 2019 Jul 2;73(25):3259–3266. DOI: 10.1016/j.jacc.2019.03.525
- Vasiljevic Z, Scarpone M, Bergami M, Yoon J, van der Schaar M, Krljanac G, Asanin M, Davidovic G, Simovic S, Manfrini O, Mickovski-Katalina N, Badimon L, Cenko E, Bugiardini R. Smoking and sex differences in first manifestation of cardiovascular disease. Atherosclerosis. 2021 Aug;330:43–51. DOI: 10.1016/j.atherosclerosis.2021.06.909
- Allagbé I, Le Faou AL, Thomas D, Airagnes G, Limosin F, Chagué F, Zeller M. Tobacco-related cardiovascular risk in women: new issues and therapeutic perspectives. Arch Cardiovasc Dis. 2021 Nov;114(11):694–706. DOI: 10.1016/j.acvd.2021.06.013
- Ji H, Gulati M, Huang TY, Kwan AC, Ouyang D, Ebinger JE, Casaletto K, Moreau KL, Skali H, Cheng S. Sex differences in association of physical activity with all-cause and cardiovascular mortality. J Am Coll Cardiol. 2024 Feb 27;83(8):783–793. DOI: 10.1016/j.jacc.2023.12.019
- Elgaddal N, Kramarow EA, Reuben C. Physical Activity Among Adults Aged 18 and Over: United States, 2020. NCHS Data Brief. 2022 Aug;(443):1–8. DOI: 10.15620/cdc:120046
- Haas DM, Ehrenthal DB, Koch MA, Catov JM, Barnes SE, Facco F, Parker CB, Mercer BM, Bairey-Merz CN, Silver RM, Wapner RJ, Simhan HN, Hoffman MK, Grobman WA, Greenland P, Wing DA, Saade GR, Parry S, Zee PC, Reddy UM, Pemberton VL, Burwen DR; National Heart, Lung, and Blood Institute nuMoM2b Heart Health Study Network. Pregnancy as a window to future cardiovascular health: design and implementation of the nuMoM2b Heart Health Study. Am J Epidemiol. 2016 Mar 15;183(6):519–530. DOI: 10.1093/aje/kwv309
- Parikh NI, Gonzalez JM, Anderson CAM, Judd SE, Rexrode KM, Hlatky MA, Gunderson EP, Stuart JJ, Vaidya D; American Heart Association Council on Epidemiology and Prevention; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Stroke Council. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation 2021;143:e902–e916. DOI: 10.1161/CIR.0000000000000961
- Honigberg MC, Zekavat SM, Aragam K, Klarin D, Bhatt DL, Scott NS, Peloso GM, Natarajan P. Long-term cardiovascular risk in women with hypertension during pregnancy. J Am Coll Cardiol. 2019 Dec 3;74(22):2743–2754. DOI: 10.1016/j.jacc.2019.09.052
- Bullough S, Lip GYH, Fauchier G, Herbert J, Sharp A, Bisson A, Ducluzeau PH, Fauchier L. The impact of gestational diabetes and gestational hypertension on future cardiovascular events: a nationwide cross-sectional cohort study. Eur J Obstet Gynecol Reprod Biol 2024;301:216–221. DOI: 10.1016/j.ejogrb.2024.08.021
- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith Sc
Jr. , Virani SS, Williams KASr. , Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–646. DOI: 10.1161/CIR.0000000000000677 - Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019 Jun;62(6):905–914. DOI: 10.1007/s00125-019-4840-2
- Wu P, Gulati M, Kwok CS, Wong CW, Narain A, O’Brien S, Chew-Graham CA, Verma G, Kadam UT, Mamas MA. Preterm delivery and future risk of maternal cardiovascular disease: a systematic review and meta-Analysis. J Am Heart Assoc. 2018 Jan 15;7(2):
e007809 . DOI: 10.1161/JAHA.117.007809 - Sima YT, Skjaerven R, Kvalvik LG, Morken NH, Klungsøyr K, Mannseth J, Sørbye LM. Birth weight in consecutive pregnancies and maternal cardiovascular disease mortality among spontaneous and iatrogenic term births: a population-based cohort study. Am J Epidemiol. 2023 Aug 4;192(8):1326–1334. DOI: 10.1093/aje/kwad075
- Kyriacou H, Al-Mohammad A, Muehlschlegel C, Foster-Davies L, Bruco MEF, Legard C, Fisher G, Simmons-Jones F, Oliver-Williams C. The risk of cardiovascular diseases after miscarriage, stillbirth, and induced abortion: a systematic review and meta-analysis. Eur Heart J Open. 2022 Oct 5;2(5):oeac065. DOI: 10.1093/ehjopen/oeac065
- Wright CE, Enquobahrie DA, Prager S, Painter I, Kooperberg C, Wild RA, Park K, Sealy-Jefferson S, Kernic MA. Pregnancy loss and risk of incident CVD within 5 years: findings from the Women’s Health Initiative. Front Cardiovasc Med. 2023 Feb 21;10:1108286. DOI: 10.3389/fcvm.2023.1108286
- Magnus MC, Fraser A, Håberg SE, Rönö K, Romundstad LB, Bergh C, Spangmose AL, Pinborg A, Gissler M, Wennerholm UB, Åsvold BO, Lawlor DA, Opdahl S. Maternal risk of cardiovascular disease after use of assisted reproductive technologies. JAMA Cardiol. 2023 Sep 1;8(9):837–845. DOI: 10.1001/jamacardio.2023.2324
- Udell JA, Lu H, Redelmeier DA. Failure of fertility therapy and subsequent adverse cardiovascular events. CMAJ. 2017 Mar 13;189(10):E391–E397. DOI: 10.1503/cmaj.160744
- Guan C, Rodriguez C, Elder-Odame P, Minhas AS, Zahid S, Baker VL, Shufelt CL, Michos ED. Assisted reproductive technology: what are the cardiovascular risks for women? Expert Rev Cardiovasc Ther 2023;21:663–673. DOI: 10.1080/14779072.2023.2266355
- Lee JJ, Cook-Wiens G, Johnson BD, Braunstein GD, Berga SL, Stanczyk FZ, Pepine CJ, Bairey Merz CN, Shufelt CL. Age at menarche and risk of cardiovascular disease outcomes: findings from the National Heart Lung and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation. J Am Heart Assoc. 2019 Jun 18;8(12):
e012406 . DOI: 10.1161/JAHA.119.012406 - Merz CN, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-DeHoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ. Cardiovascular Disease and 10-Year Mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Womens Health. 2016 Sep;25(9):875–881. DOI: 10.1089/jwh.2015.5441
- Oliver-Williams C, Vassard D, Pinborg A, Schmidt L. Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study. Eur J Prev Cardiol. 2021 Oct 13;28(12):e39–e41. DOI: 10.1177/2047487320939674
- Shufelt CL, Torbati T, Dutra E. Hypothalamic amenorrhea and the long-term health consequences. Semin Reprod Med. 2017 May;35(3):256–262. DOI: 10.1055/s-0037-1603581
- Shufelt CL, Saadedine M, Cook-Wiens G, Pisarska MD, Manson JE, Berga SL, Arditi M, Shah PK, Bairey Merz CN. Functional hypothalamic amenorrhea and preclinical cardiovascular disease. J Clin Endocrinol Metab. 2023 Dec 21;109(1):e51–e57. DOI: 10.1210/clinem/dgad498
- Christ JP, Gunning MN, Palla G, Eijkemans MJC, Lambalk CB, Laven JSE, Fauser BCJM. Estrogen deprivation and cardiovascular disease risk in primary ovarian insufficiency. Fertil Steril. 2018 Apr;109(4):594–600.e1. DOI: 10.1016/j.fertnstert.2017.11.035
- El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, Limacher MC, Manson JE, Stefanick ML, Allison MA; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020 Dec 22;142(25):e506–e532. DOI: 10.1161/CIR.0000000000000912
- Roeters van Lennep JE, Heida KY, Bots ML, Hoek A; collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23(2):178–186. DOI: 10.1177/2047487314556004
- Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, Kavousi M, Franco OH. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis. JAMA Cardiol. 2016;1(7):767–776. DOI: 10.1001/jamacardio.2016.2415
- Peters SA, Woodward M. Women’s reproductive factors and incident cardiovascular disease in the UK Biobank. Heart. 2018;104(13):1069–1075. DOI: 10.1136/heartjnl-2017-312289
- Kamińska MS, Schneider-Matyka D, Rachubińska K, Panczyk M, Grochans E, Cybulska AM. Menopause predisposes women to increased risk of cardiovascular disease. J Clin Med. 2023 Nov 13;12(22):7058. DOI: 10.3390/jcm12227058
- Abbas SZ, Sangawan V, Das A, Pandey AK. Assessment of cardiovascular risk in natural and surgical menopause. Indian J Endocrinol Metab. 2018 Mar–Apr;22(2):223–228. DOI: 10.4103/ijem.IJEM_620_17
- Parasar P, Ozcan P, Terry KL. Endometriosis: Epidemiology, diagnosis and clinical management. Curr Obstet Gynecol Rep. 2017;6(1):34–41. DOI: 10.1007/s13669-017-0187-1
- Marchandot B, Curtiaud A, Matsushita K, Trimaille A, Host A, Faller E, Garbin O, Akladios C, Jesel L, Morel O. Endometriosis and cardiovascular disease. Eur Heart J Open. 2022;2(1):oeac001. DOI: 10.1093/ehjopen/oeac001
- Parsa S, Noroozpoor R, Dehghanbanadaki H, Khateri S, Moradi Y. Endometriosis and risk of cardiovascular disease: a systematic review and meta-analysis. BMC Public Health. 2025 Jan 21;25(1):245. DOI: 10.1186/s12889-025-21486-0
- Gulati M, Mulvagh SL. The connection between the breast and heart in a woman: breast cancer and cardiovascular disease. Clin Cardiol. 2018;41(2):253–257. DOI: 10.1002/clc.22886
- Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–999. DOI: 10.1056/NEJMoa1209825
- Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):
e000472 . DOI: 10.1161/JAHA.113.000472 - Allen TS, Bui QM, Petersen GM, Mantey R, Wang J, Nerlekar N, Eghtedari M, Daniels LB. Automated breast arterial calcification score is associated with cardiovascular outcomes and mortality. JACC Adv 2024;3:101283. DOI: 10.1016/j.jacadv.2024.101283
- Minssen L, Dao TH, Quang AV, Martin L, Andureau E, Luciani A, Meyblum E, Derumeaux G, Deux JF. Breast arterial calcifications on mammography: a new marker of cardiovascular risk in asymptomatic middle age women? Eur Radiol 2022;32:4889–4897. DOI: 10.1007/s00330-022-08571-3
- Iribarren C, Chandra M, Lee C, Sanchez G, Sam DL, Azamian FF, Cho HM, Ding H, Wong ND, Molloi S. Breast arterial calcification: a novel cardiovascular risk enhancer among postmenopausal women. Circ Cardiovasc Imaging 2022;15:
e013526 . DOI: 10.1161/CIRCIMAGING.121.013526 - Strelow B, O’Laughlin D, Anderson T, Cyriac J, Buzzard J, Klindworth A. Menopause decoded: what’s happening and how to manage it. J Prim Care Community Health. 2024;15:21501319241307460. DOI: 10.1177/21501319241307460
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168. DOI: 10.1097/gme.0b013e31824d8f40
- Ambikairajah A, Walsh E, Cherbuin N. A review of menopause nomenclature. Reprod Health. 2022 Jan 31;19(1):29. DOI: 10.1186/s12978-022-01336-7
- Randolph JF
Jr , Sowers M, Bondarenko IV, Harlow SD, Luborsky JL, Little RJ. Change in estradiol and follicle-stimulating hormone across the early menopausal transition: effects of ethnicity and age. J Clin Endocrinol Metab. 2004 Apr;89(4):1555–1561. DOI: 10.1210/jc.2003-031183 - Blümel JE, Lavín P, Vallejo MS, Sarrá S. Menopause or climacteric, just a semantic discussion or has it clinical implications? Climacteric. 2014;17(3):235–241. DOI: 10.3109/13697137.2013.838948
- Schoenaker DAJM, Jackson CA, Rowlands J V, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause: A systematic review and meta-analyses of studies across six continents. Int J Epidemiol. 2014;43(5):1542–1562. DOI: 10.1093/ije/dyu094
- Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. 2010;13(5):419–428. DOI: 10.3109/13697137.2010.507886
- Grisotto G, Farago JS, Taneri PE, Wehrli F, Roa-Díaz ZM, Minder B, Glisic M, Gonzalez-Jaramillo V, Voortman T, Marques-Vidal P, Franco OH, Muka T. Dietary factors and onset of natural menopause: A systematic review and meta-analysis. Maturitas. 2022;159(November 2021):15–32. DOI: 10.1016/j.maturitas.2021.12.008
- Sapre S, Thakur R. Lifestyle and dietary factors determine age at natural menopause. J Midlife Health. 2014 Jan;5(1):3–5. DOI: 10.4103/0976-7800.127779
- Hayatbakhsha M, Clavarino A, Williams GM, Sina M, Najman JM. Cigarette smoking and age of menopause: A large prospective study. Maturitas. 2012;72:346–352. DOI: 10.1016/j.maturitas.2012.05.004
- Gold EB, Crawford SL, Avis NE, Crandall CJ, Matthews KA, Waetjen LE, Lee JS, Thurston R, Vuga M, Harlow SD. Factors related to age at natural menopause: Longitudinal analyses from SWAN. Am J Epidemiol. 2013;178(1):70–83. DOI: 10.1093/aje/kws421
- Kok HS, van Asselt KM, van der Schouw YT, van der Tweel I, Peeters PH, Wilson PW, Pearson PL, Grobbee DE. Heart disease risk determines menopausal age rather than the reverse. J Am Coll Cardiol. 2006;47(10):1976–1983. DOI: 10.1016/j.jacc.2005.12.066
- Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, Januzzi JL
Jr , Scott NS, Natarajan P. Association of premature natural and surgical menopause with incident cardiovascular disease. JAMA. 2019;322(24):2411–2421. DOI: 10.1001/jama.2019.19191 - Honigberg MC, Zekavat SM, Niroula A, Griffin GK, Bick AG, Pirruccello JP, Nakao T, Whitsel EA, Farland LV, Laurie C, Kooperberg C, Manson JE, Gabriel S, Libby P, Reiner AP, Ebert BL; NHLBI Trans-Omics for Precision Medicine Program; Natarajan P. Premature menopause, clonal hematopoiesis, and coronary artery disease in postmenopausal women. Circulation. 2021;143(5):410–423. DOI: 10.1161/CIRCULATIONAHA.120.051775
- European Society of Human Reproduction and Embryology (ESHRE). Premature ovarian insufficiency (POI): guideline 2024 [Internet]. ESHRE; 2024. Available from:
https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Premature-ovarian-insufficiency - Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis. Climacteric. 2019 Aug;22(4):403–411. DOI: 10.1080/13697137.2019.1574738
- Dave A, Patel DJ, Shrivastava D, Chaudhari K, Manchanda R. Considerations in premature menopause: a review. Cureus. 2024 Sep 19;16(9):
e69744 . DOI: 10.7759/cureus.69744 - British Menopause Society. BMS consensus statement: Premature ovarian insufficiency (POI) [Internet]. 2024. Available from:
https://thebms.org.uk/publications/consensus-statements/premature-ovarian-insufficiency/ - Khadilkar SS, Samant M. Oophorectomy: When and Why? A Novel Risk Stratification Tool as an Aid to Decision Making at Gynecological Surgeries. J Obstet Gynaecol India. 2023 Dec;73(6):471–476. DOI: 10.1007/s13224-023-01924-y
- Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, Bandinelli S, Salfati E, Manson JE, Quach A, Kusters CD, Kuh D, Wong A, Teschendorff AE, Widschwendter M, Ritz BR, Absher D, Assimes TL, Horvath S. Menopause accelerates biological aging. Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9327–9332. DOI: 10.1073/pnas.1604558113
- Motlani V, Motlani G, Pamnani S, Sahu A, Acharya N. Endocrine changes in postmenopausal women: a comprehensive view. Cureus. 2023 Dec 29;15(12):
e51287 . DOI: 10.7759/cureus.51287 - Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021 Jan 1;106(1):1–15. DOI: 10.1210/clinem/dgaa764
- Monteleone P, Mascagni G, Giannini A, Genazzani AR, Simoncini T. Symptoms of menopause – global prevalence, physiology and implications. Nat Rev Endocrinol. 2018 Apr;14(4):199–215. DOI: 10.1038/nrendo.2017.180
- Huang DR, Goodship A, Webber I, Alaa A, Sasco ER, Hayhoe B, El-Osta A. Experience and severity of menopause symptoms and effects on health-seeking behaviours: a cross-sectional online survey of community dwelling adults in the United Kingdom. BMC Womens Health. 2023 Jul 14;23(1):373. DOI: 10.1186/s12905-023-02506-w
- Fang Y, Liu F, Zhang X, Chen L, Liu Y, Yang L, Zheng X, Liu J, Li K, Li Z. Mapping global prevalence of menopausal symptoms among middle-aged women: a systematic review and meta-analysis. BMC Public Health. 2024 Jul 2;24(1):1767. DOI: 10.1186/s12889-024-19280-5
- Pertynska-Marczewska M, Pertynski T. Non-hormonal pharmacological interventions for managing vasomotor symptoms – how can we help: 2024 landscape. Eur J Obstet Gynecol Reprod Biol. 2024 Nov;302:141–148. DOI: 10.1016/j.ejogrb.2024.09.013
- Zeleke BM, Bell RJ, Billah B, Davis SR. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study. Fertil Steril. 2016 Jan;105(1):149–155.e1. DOI: 10.1016/j.fertnstert.2015.09.017
- Koysombat K, Tsoutsouki J, Patel AH, Comninos AN, Dhillo WS, Abbara A. Kisspeptin and neurokinin B: roles in reproductive health. Physiol Rev. 2025 Apr 1;105(2):707–764. DOI: 10.1152/physrev.00015.2024
- Jeon GH. Insomnia in postmenopausal women: how to approach and treat it? J Clin Med. 2024 Jan 12;13(2):428. DOI: 10.3390/jcm13020428
- Gava G, Orsili I, Alvisi S, Mancini I, Seracchioli R, Meriggiola MC. Cognition, mood and sleep in menopausal transition: the role of menopause hormone therapy. Medicina (Kaunas). 2019 Oct 1;55(10):668. DOI: 10.3390/medicina55100668
- Khadilkar SV, Patil VA. Sex Hormones and Cognition: Where Do We Stand? J Obstet Gynaecol India. 2019 Aug;69(4):303–312. DOI: 10.1007/s13224-019-01223-5
- Maki PM, Jaff NG. Brain fog in menopause: a health-care professional’s guide for decision-making and counseling on cognition. Climacteric. 2022 Dec;25(6):570–578. DOI: 10.1080/13697137.2022.2122792
- Conde DM, Verdade RC, Valadares ALR, Mella LFB, Pedro AO, Costa-Paiva L. Menopause and cognitive impairment: a narrative review of current knowledge. World J Psychiatry. 2021 Aug 19;11(8):412–428. DOI: 10.5498/wjp.v11.i8.412
- Whiteley J, DiBonaventura M, Wagner JS, Alvir J, Shah S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J Womens Health. 2013 Nov;22(11):983–990. DOI: 10.1089/jwh.2012.3719
- Brzozowska M, Lewiński A. Changes of androgens levels in menopausal women. Prz Menopauzalny. 2020 Dec;19(4):151–154. DOI: 10.5114/pm.2020.101941
- Wasnik VB, Acharya N, Mohammad S. Genitourinary Syndrome of Menopause: A Narrative Review Focusing on Its Effects on the Sexual Health and Quality of Life of Women. Cureus. 2023 Nov 2;15(11):
e48143 . DOI: 10.7759/cureus.48143 - Trento SRSS, Madeiro A, Rufino AC. Sexual function and associated factors in postmenopausal women. Rev Bras Ginecol Obstet. 2021 Jul;43(7):522–529. DOI: 10.1055/s-0041-1735128
- Angelou K, Grigoriadis T, Diakosavvas M, Zacharakis D, Athanasiou S. The genitourinary syndrome of menopause: an overview of the recent data. Cureus. 2020 Apr 8;12(4):
e7586 . DOI: 10.7759/cureus.7586 - Lu CB, Liu PF, Zhou YS, Meng FC, Qiao TY, Yang XJ, Li XY, Xue Q, Xu H, Liu Y, Han Y, Zhang Y. Musculoskeletal pain during the menopausal transition: a systematic review and meta-analysis. Neural Plast. 2020 Nov 25;2020:8842110. DOI: 10.1155/2020/8842110
- Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric. 2024 Oct;27(5):466–472. DOI: 10.1080/13697137.2024.2380363
- Bhasin S, Travison TG, Manini TM, Patel S, Pencina KM, Fielding RA, Magaziner JM, Newman AB, Kiel DP, Cooper C, Guralnik JM, Cauley JA, Arai H, Clark BC, Landi F, Schaap LA, Pereira SL, Rooks D, Woo J, Woodhouse LJ, Binder E, Brown T, Shardell M, Xue QL, DʼAgostino RB
Sr. , Orwig D, Gorsicki G, Correa-De-Araujo R, Cawthon PM. Sarcopenia definition: the position statements of the Sarcopenia Definition and Outcomes Consortium. J Am Geriatr Soc. 2020;68(7):1410–1418. DOI: 10.1111/jgs.16372 - Xiao PL, Cui AY, Hsu CJ, Peng R, Jiang N, Xu XH, Ma YG, Liu D, Lu HD. Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int. 2022 Oct;33(10):2137–2153. DOI: 10.1007/s00198-022-06454-3
- Bhatnagar A, Kekatpure AL. Postmenopausal osteoporosis: a literature review. Cureus. 2022 Sep 20;14(9):
e29367 . DOI: 10.7759/cureus.29367 - Hemmati E, Mirghafourvand M, Mobasseri M, Shakouri SK, Mikaeli P, Farshbaf-Khalili A. Prevalence of primary osteoporosis and low bone mass in postmenopausal women and related risk factors. J Educ Health Promot. 2021 Jun 30;10:204. DOI: 10.4103/jehp.jehp_945_20
- Zouboulis CC, Blume-Peytavi U, Kosmadaki M, Roó E, Vexiau-Robert D, Kerob D, Goldstein SR. Skin, hair and beyond: the impact of menopause. Climacteric. 2022 Oct;25(5):434–442. DOI: 10.1080/13697137.2022.2050206
- Carpenter JS, Sheng Y, Pike C, Elomba CD, Alwine JS, Chen CX, Tisdale JE. Correlates of palpitations during menopause: a scoping review. Womens Health (Lond). 2022 Jan–Dec;18:17455057221112267. DOI: 10.1177/17455057221112267
- Darvish S, Murray KO, Ludwig KR, Avalani KH, Craighead DH, Freeberg KA, Bevers S, Reisz JA, D’Alessandro A, Moreau KL, Seals DR, Rossman MJ. Preservation of vascular endothelial function in late-onset postmenopausal women. Circ Res. 2025 Feb 28;136(5):455–469. DOI: 10.1161/CIRCRESAHA.124.325639
- Aryan L, Younessi D, Zargari M, Banerjee S, Agopian J, Rahman S, Borna R, Ruffenach G, Umar S, Eghbali M. The Role of Estrogen Receptors in Cardiovascular Disease. Int J Mol Sci. 2020 Jun 17;21(12):1–26. DOI: 10.3390/ijms21124314
- Fasero M, Coronado PJ. Cardiovascular disease risk in women with menopause. J Clin Med. 2025 May 23;14(11):3663. DOI: 10.3390/jcm14113663
- SenthilKumar G, Katunaric B, Bordas-Murphy H, Sarvaideo J, Freed JK. Estrogen and the vascular endothelium: the unanswered questions. Endocrinology. 2023 Apr 17;164(6):1–13. DOI: 10.1210/endocr/bqad079
- Schreinlechner M, Noflatscher M, Reinstadler SJ, Sommer P, Lener D, Reiser E, Theurl M, Kirchmair R, Bauer A, Marschang P. Early onset of menopause is associated with increased peripheral atherosclerotic plaque volume and progression. Atherosclerosis. 2020 Mar;297:25–31. DOI: 10.1016/j.atherosclerosis.2020.01.023
- Tasić T, Tadić M, Lozić M. Hypertension in women. Front Cardiovasc Med. 2022 Jun 3:1–7. DOI: 10.3389/fcvm.2022.905504
- Ryczkowska K, Adach W, Janikowski K, Banach M, Bielecka-Dabrowa A. Menopause and women’s cardiovascular health: is it really an obvious relationship? Arch Med Sci. 2022 Dec 10;19(2):458–466. DOI: 10.5114/aoms/157308
- Anagnostis P, Theocharis P, Lallas K, Konstantis G, Mastrogiannis K, Bosdou JK, Lambrinoudaki I, Stevenson JC, Goulis DG. Early menopause is associated with increased risk of arterial hypertension: a systematic review and meta-analysis. Maturitas. 2020 May;135:74–79. DOI: 10.1016/j.maturitas.2020.03.006
- Li C, Wei M, Mo L, Velu P, Prabahar K, Găman MA, Chen M. The effect of tibolone treatment on apolipoproteins and lipoprotein(a) concentrations in postmenopausal women: a meta-analysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2024;292:8–16. DOI: 10.1016/j.ejogrb.2023.10.020
- Genazzani A, Petrillo T, Semprini E, Aio C, Foschi M, Ambrosetti F, Sponzilli A, Ricciardiello F, Battipaglia C. Metabolic syndrome, insulin resistance and menopause: the changes in body structure and the therapeutic approach. Gynecol Reprod Endocrinol Metab. 2023;4(2–3):86–91. DOI: 10.53260/grem.234026
- Ko SH, Jung Y. Energy metabolism changes and dysregulated lipid metabolism in postmenopausal women. Nutrients. 2021;13(12):4556. DOI: 10.3390/nu13124556
- Opoku AA, Abushama M, Konje JC. Obesity and menopause. Best Pract Res Clin Obstet Gynaecol. 2023 Jun;88:102348. DOI: 10.1016/j.bpobgyn.2023.102348
- Rehman A, Lathief S, Charoenngam N, Pal L. Aging and Adiposity-Focus on Biological Females at Midlife and Beyond. Int J Mol Sci. 2024 Mar 4;25(5):2972. DOI: 10.3390/ijms25052972
- Liu Y, Ding J, Bush TL, Longenecker JC, Nieto FJ, Golden SH, Szklo M. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am J Epidemiol. 2001 Sep 15;154(6):489–494. DOI: 10.1093/aje/154.6.489
- Hallajzadeh J, Khoramdad M, Izadi N, Karamzad N, Almasi-Hashiani A, Ayubi E, Qorbani M, Pakzad R, Hasanzadeh A, Sullman MJM, Safiri S. Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies. Menopause. 2018 Oct;25(10):1155–1164. DOI: 10.1097/GME.0000000000001136
- Mauvais-Jarvis F, Manson JE, Stevenson JC, Fonseca VA. Menopausal Hormone Therapy and Type 2 Diabetes Prevention: Evidence, Mechanisms, and Clinical Implications. Endocr Rev. 2017 Jun 1;38(3):173–188. DOI: 10.1210/er.2016-1146
- Crandall CJ, Barrett-Connor E. Endogenous sex steroid levels and cardiovascular disease in relation to the menopause: a systematic review. Endocrinol Metab Clin North Am. 2013 Jun;42(2):227–253. DOI: 10.1016/j.ecl.2013.02.003
- Panay N, Ang SB, Cheshire R, Goldstein SR, Maki P, Nappi RE; International Menopause Society Board. Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper. Climacteric. 2024 Oct;27(5):441–457. DOI: 10.1080/13697137.2024.2394950
- Academic Committee of the Korean Society of Menopause; Lee SR, Cho MK, Cho YJ, Chun S, Hong SH, Hwang KR, Jeon GH, Joo JK, Kim SK, Lee DO, Lee DY, Lee ES, Song JY, Yi KW, Yun BH, Shin JH, Chae HD, Kim T. The 2020 menopausal hormone therapy guidelines. J Menopausal Med. 2020 Aug;26(2):69–98. DOI: 10.6118/jmm.20000
- North America Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. DOI: 10.1097/GME.0000000000002028
- Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel Sanchez R, Knight B. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;2015(3):CD002229. DOI: 10.1002/14651858.CD002229.pub4
- Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013 Oct 2;310(13):1353–1368. DOI: 10.1001/jama.2013.278040
- Rossouw JE, Aragaki AK, Manson JE, Szmuilowicz ED, Harrington LB, Johnson KC, Allison M, Haring B, Saquib N, Shadyab AH, Rexrode KM, Liu L, Mouton CP, LaCroix AZ. Menopausal hormone therapy and cardiovascular diseases in women with vasomotor symptoms: a secondary analysis of the Women’s Health Initiative randomized clinical trials. JAMA Intern Med 2025;185:1330–1339. DOI: 10.1001/jamainternmed.2025.4510
- Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020 Jan 30;382(5):446–455. DOI: 10.1056/NEJMcp1714787
- Cintron D, Lipford M, Larrea-Mantilla L, Spencer-Bonilla G, Lloyd R, Gionfriddo MR, Gunjal S, Farrell AM, Miller VM, Murad MH. Efficacy of menopausal hormone therapy on sleep quality: systematic review and meta-analysis. Endocrine. 2017 Mar;55(3):702–711. DOI: 10.1007/s12020-016-1072-9
- Toffol E, Heikinheimo O, Partonen T. Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review. Menopause. 2015 May;22(5):564–578. DOI: 10.1097/GME.0000000000000323
- Gnanasegar R, Wolfman W, Galan LH, Cullimore A, Shea AK. Does menopause hormone therapy improve symptoms of depression? Findings from a specialized menopause clinic. Menopause. 2024 Apr 1;31(4):320–325. DOI: 10.1097/GME.0000000000002325
- Biehl C, Plotsker O, Mirkin S. A systematic review of the efficacy and safety of vaginal estrogen products for the treatment of genitourinary syndrome of menopause. Menopause. 2019 Apr;26(4):431–453. DOI: 10.1097/GME.0000000000001221
- Ferrante KL, Wasenda EJ, Jung CE, Adams-Piper ER, Lukacz ES. Vaginal estrogen for the prevention of recurrent urinary tract infection in postmenopausal women: a randomized clinical trial. Female Pelvic Med Reconstr Surg. 2021 Feb 1;27(2):112–117. DOI: 10.1097/SPV.0000000000000749
- Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause. 2012 Jan;19(1):109–117. DOI: 10.1097/gme.0b013e31821f92df
- Meziou N, Scholfield C, Taylor CA, Armstrong HL. Hormone therapy for sexual function in perimenopausal and postmenopausal women: a systematic review and meta-analysis update. Menopause. 2023 Jun 1;30(6):659–671. DOI: 10.1097/GME.0000000000002185
- Liu Y, Li C. Hormone therapy and biological aging in postmenopausal women. JAMA Netw Open. 2024 Aug 1;7(8):
e2430839 . DOI: 10.1001/jamanetworkopen.2024.30839 - Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017;13(4):220–231. DOI: 10.1038/nrendo.2016.164
- Arayici ME, Kilic ME, Yilmaz MB. The impact of hormone replacement therapy on the risk of heart failure in postmenopausal women: a meta-analysis of clinical and observational studies. Pharmacoepidemiol Drug Saf. 2024;33(10):
e70029 . DOI: 10.1002/pds.70029 - Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: it is about time and timing. Cancer J. 2022;28(3):208–223. DOI: 10.1097/PPO.0000000000000591
- Gosset A, Pouillès JM, Trémollieres F. Menopausal hormone therapy for the management of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101551. DOI: 10.1016/j.beem.2021.101551
- Câmara SMA, Macêdo PRS, Velez MP. Menopause hormone therapy and sarcodynapenia: the Canadian Longitudinal Study on Aging. Menopause. 2023 Mar 1;30(3):254–259. DOI: 10.1097/GME.0000000000002127
- Tian Y, Lin Y, Qu C, Arndt V, Baurley JW, Berndt SI, Bien SA, Bishop DT, Brenner H, Buchanan DD, Budiarto A, Campbell PT, Carreras-Torres R, Casey G, Chan AT, Chen R, Chen X, Conti DV, Díez-Obrero V, Dimou N, Drew DA, Figueiredo JC, Gallinger S, Giles GG, Gruber SB, Gunter MJ, Harlid S, Harrison TA, Hidaka A, Hoffmeister M, Huyghe JR, Jenkins MA, Jordahl KM, Joshi AD, Keku TO, Kawaguchi E, Kim AE, Kundaje A, Larsson SC, Marchand LL, Lewinger JP, Li L, Moreno V, Morrison J, Murphy N, Nan H, Nassir R, Newcomb PA, Obón-Santacana M, Ogino S, Ose J, Pardamean B, Pellatt AJ, Peoples AR, Platz EA, Potter JD, Prentice RL, Rennert G, Ruiz-Narvaez EA, Sakoda LC, Schoen RE, Shcherbina A, Stern MC, Su YR, Thibodeau SN, Thomas DC, Tsilidis KK, van Duijnhoven FJB, Van Guelpen B, Visvanathan K, White E, Wolk A, Woods MO, Wu AH, Peters U, Gauderman WJ, Hsu L, Chang-Claude J. Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk. Br J Cancer. 2024 Jun;130(10):1687–1696. DOI: 10.1038/s41416-024-02638-2
- Nakhostin L, Stadler A, Stute P. Impact of menopausal hormone therapy on colorectal cancer risk: a systematic review. Clin Endocrinol (Oxf). 2021 Sep;95(3):390–397. DOI: 10.1111/cen.14469
- Beral V, Bull D, Reeves G; Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005 Apr 30–May 6.365(9470):1543–1551. DOI: 10.1016/S0140-6736(05)66455-0
- Chlebowski RT, Anderson GL, Sarto GE, Haque R, Runowicz CD, Aragaki AK, Thomson CA, Howard BV, Wactawski-Wende J, Chen C, Rohan TE, Simon MS, Reed SD, Manson JE. Continuous combined estrogen plus progestin and endometrial cancer: the Women’s Health Initiative randomized trial. J Natl Cancer Inst. 2015 Dec 14;108(3):djv350. DOI: 10.1093/jnci/djv350
- Chlebowski RT, Aragaki AK, Pan K, Mortimer JE, Johnson KC, Wactawski-Wende J, LeBoff MS, Lavasani S, Lane D, Nelson RA, Manson JE. Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis. Breast Cancer Res Treat. 2024 Jul;206(1):177–184. DOI: 10.1007/s10549-024-07307-9
- Maki PM. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause. 2013 Jun;20(6):695–709. DOI: 10.1097/GME.0b013e3182960cf8
- Andy C, Nerattini M, Jett S, Carlton C, Zarate C, Boneu C, Fauci F, Ajila T, Battista M, Pahlajani S, Christos P, Fink ME, Williams S, Brinton RD, Mosconi L. Systematic review and meta-analysis of the effects of menopause hormone therapy on cognition. Front Endocrinol. 2024;15:1290355. DOI: 10.3389/fendo.2024.1350318
- Sharma A, Davies R, Kapoor A, Islam H, Webber L, Jayasena CN. The effect of hormone replacement therapy on cognition and mood. Clin Endocrinol (Oxf). 2023 Mar;98(3):285–295. DOI: 10.1111/cen.14856
- Saleh RNM, Hornberger M, Ritchie CW, Minihane AM. Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort. Alzheimers Res Ther. 2023 Jan 9;15(1):10. DOI: 10.1186/s13195-022-01121-5
- Nerattini M, Jett S, Andy C, Carlton C, Zarate C, Boneu C, Battista M, Pahlajani S, Loeb-Zeitlin S, Havryulik Y, Williams S, Christos P, Fink M, Brinton RD, Mosconi L. Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer’s disease and dementia. Front Aging Neurosci. 2023 Oct 23;15:1260427. DOI: 10.3389/fnagi.2023.1260427
- Bergendal A, Kieler H, Sundström A, Hirschberg AL, Kocoska-Maras L. Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause. 2016;23(6):593–599. DOI: 10.1097/GME.0000000000000611
- Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:1–14. DOI: 10.1136/bmj.k4810
- Scarabin PY. Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric. 2018 Aug;21(4):341–345. DOI: 10.1080/13697137.2018.1446931
- Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, Elbaz A, Scarabin PY. Postmenopausal hormone therapy and risk of stroke: impact of the route of estrogen administration and type of progestogen. Stroke. 2016 Jul;47(7):1734–1741. DOI: 10.1161/STROKEAHA.116.013052
- Choo SP, Park H, Park H, Lee I, Cho S, Kim C, Lee KY, Lee JH, Kim JY. Menopausal Hormone Therapy and the Risk of Stroke: A Nationwide Cohort Study. Yonsei Med J. 2025 Jul;66(7):429–437. DOI: 10.3349/ymj.2024.0053
- Løkkegaard E, Nielsen LH, Keiding N. Risk of Stroke With Various Types of Menopausal Hormone Therapies: A National Cohort Study. Stroke. 2017 Aug;48(8):2266–2269. DOI: 10.1161/STROKEAHA.117.017132
- Renoux C, Dell’Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010 Jun 3;340:c2519. DOI: 10.1136/bmj.c2519
- Rahkola-Soisalo P, Savolainen-Peltonen H, Gissler M, et al. Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy. Int Urogynecol J. 2019 Feb;30(2):251–256. DOI: 10.1007/s00192-018-3682-7
- Rahkola-Soisalo P, Savolainen-Peltonen H, Gissler M, Hoti F, Vattulainen P, Ylikorkala O, Mikkola TS. Postmenopausal hormone therapy is accompanied by elevated risk for uterine prolapse. Menopause. 2019 Feb;26(2):140–144. DOI: 10.1007/s00192-018-3682-7
- Mastorakos G, Iatrakis G, Zervoudis S, Syropoulou S. Progestins and the risk of breast cancer. Acta Endocrinol (Buchar). 2021 Apr–Jun;17(1):90–100. DOI: 10.4183/aeb.2021.90
- Gompel A. Progesterone and endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2020 Nov;69:95–107. DOI: 10.1016/j.bpobgyn.2020.05.003
- Fournier A, Cairat M, Severi G, Gunter MJ, Rinaldi S, Dossus L. Use of menopausal hormone therapy and ovarian cancer risk in a French cohort study. J Natl Cancer Inst. 2023 Jun 8;115(6):671–679. DOI: 10.1093/jnci/djad035
- Collaborative Group on Epidemiological Studies of Ovarian Cancer; Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet. 2015 May 9;385(9980):1835–1842. DOI: 10.1016/S0140-6736(14)61687-1
- Løkkegaard ECL, Mørch LS. Tibolone and risk of gynecological hormone-sensitive cancer. Int J Cancer. 2018 Jun 15;142(12):2435–2440. DOI: 10.1002/ijc.31267
- Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J; WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation. 2006 May 23;113(20):2425–2434. DOI: 10.1161/CIRCULATIONAHA.105.594077
- Yang Z, Hu Y, Zhang J, Xu L, Zeng R, Kang D. Estradiol therapy and breast cancer risk in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Gynecol Endocrinol. 2017 Feb;33(2):87–92. DOI: 10.1080/09513590.2016.1248932
- Baek JK, Kim HI, Kang MJ, Seon KE, Kim EH, Seo SK. Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea. Climacteric. 2022 Oct;25(5):516–522. DOI: 10.1080/13697137.2022.2077096
- Busund M, Ursin G, Lund E, Chen SLF, Rylander C. Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study. Breast Cancer Res. 2024 Nov 4;26(1):151. DOI: 10.1186/s13058-024-01897-4
- Cho L, Kaunitz AM, Faubion SS, Hayes SN, Lau ES, Pristera N, Scott N, Shifren JL, Shufelt CL, Stuenkel CA, Lindley KJ; ACC CVD in Women Committee. Rethinking menopausal hormone therapy: for whom, what, when, and how long? Circulation. 2023 Feb 14;147(7):597–610. DOI: 10.1161/CIRCULATIONAHA.122.061559
- Baik SH, Baye F, McDonald CJ. Use of menopausal hormone therapy beyond age 65 years and its effects on women’s health outcomes by types, routes, and doses. Menopause. 2024;31(5):363–437. DOI: 10.1097/GME.0000000000002335
- Canadian Agency for Drugs and Technologies in Health. Comparative evidence between transdermal and oral menopausal hormone therapy: drugs [Internet]. Ottawa (ON): CADTH; 2025 Apr. Report No.: RD0073. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK614933/ - Renoux C, Dell’Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010;8(5):979–986. DOI: 10.1111/j.1538-7836.2010.03839.x
- Canonico M, Oger E, Conard J, Meyer G, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; EStrogen and THromboEmbolism Risk (ESTHER) Study Group. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost. 2006;4(6):1259–1265. DOI: 10.1111/j.1538-7836.2006.01933.x
- Hicks A, Robson D, Tellis B, Smith S, Dunkley S, Baber R. Safety of menopause hormone therapy in postmenopausal women at higher risk of venous thromboembolism: a systematic review. Climacteric. 2025 Jun 9:1–26. DOI: 10.1080/13697137.2025.2503874
- Olié V, Plu-Bureau G, Conard J, Horellou MH, Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488–493. DOI: 10.1097/gme.0b013e3181f9f7c3
- Margarido PF, Bagnoli VR, Maggio da Fonseca A, Maciel GA, Soares JM
Jr , D’Amico EA, Baracat EC. Transdermal estrogen therapy effects on fibrinogen levels in women with a past history of venous thromboembolism: a pilot study. Clin Exp Obstet Gynecol. 2011;38(3):232–235. - Sweetland S, Beral V, Balkwill A, Liu B, Benson VS, Canonico M, Green J, Reeves GK; Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277–2286. DOI: 10.1111/j.1538-7836.2012.04919.x
- Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, Alhenc-Gelas M, Lévesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation. 2005;112(22):3495–3500. DOI: 10.1161/CIRCULATIONAHA.105.565556
- Straczek C, Alhenc-Gelas M, Aubry ML, Scarabin PY. Genetic variation at the estrogen receptor alpha locus in relation to venous thromboembolism risk among postmenopausal women. J Thromb Haemost. 2005;3(7):1535–1537. DOI: 10.1111/j.1538-7836.2005.01450.x
- Canonico M, Bouaziz E, Carcaillon L, Verstuyft C, Guiochon-Mantel A, Becquemont L, Scarabin PY; Estrogen and Thromboembolism Risk (ESTHER) Study Group. Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab. 2008;93(8):3082–3087. DOI: 10.1210/jc.2008-0450
- Bińkowska M, Woroń J. Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134–143. DOI: 10.5114/pm.2015.52154
- Armeni E, Paschou SA, Goulis DG, Lambrinoudaki I. Hormone therapy regimens for managing the menopause and premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab. 2021 Dec;35(6):101561. DOI: 10.1016/j.beem.2021.101561
- Stute P, Walker LJ, Eicher A, Pavicic E, Kolokythas A, Theis S, von Gernler M, von Wolff M, Vollrath S. Progestogens for endometrial protection in combined menopausal hormone therapy: a systematic review. Best Pract Res Clin Endocrinol Metab. 2024 Jan;38(1):101815. DOI: 10.1016/j.beem.2023.101815
- Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas. 2011 Dec;70(4):354–360. DOI: 10.1016/j.maturitas.2011.10.002
- Canonico M, Fournier A, Carcaillon L, Olié V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3 N cohort study. Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):340–345. DOI: 10.1161/ATVBAHA.109.196022
- Stevenson JC, Rozenberg S, Maffei S, Egarter C, Stute P, Römer T. Progestogens as a component of menopausal hormone therapy: the right molecule makes the difference. Drugs Context. 2020 Dec 2;9:2020-10-1. DOI: 10.7573/dic.2020-10-1
- Ruan X, Mueck AO. Optimizing menopausal hormone therapy: for treatment and prevention, menstrual regulation, and reduction of possible risks. Glob Health J 2022;6:61–69. DOI: 10.1016/j.glohj.2022.03.003
- Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V, Marata AM, Magrini N, D’Amico R, Bassi C, Maestri E. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016 Oct 12;10(10):CD008536. DOI: 10.1002/14651858.CD008536.pub3
- Johansson T, Karlsson T, Bliuc D, Schmitz D, Ek WE, Skalkidou A, Center JR, Johansson Å. Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial. BMJ. 2024 Nov 27;387:
e078784 . DOI: 10.1136/bmj-2023-078784 - Lindsay R, Gallagher JC, Kagan R, Pickar JH, Constantine G. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009 Sep;92(3):1045–1052. DOI: 10.1016/j.fertnstert.2009.02.093
- Pazhekattu R, Lau AN, Adachi JD. The tissue-selective estrogen complex: a review of current evidence. Rheumatol Ther. 2015 Jun;2(1):47–58. DOI: 10.1007/s40744-015-0013-z
- Mirkin S, Pickar JH. Management of osteoporosis and menopausal symptoms: focus on bazedoxifene/conjugated estrogen combination. Int J Womens Health. 2013 Aug 7;5:465–475. DOI: 10.2147/IJWH.S39455
- Crandall CJ, Diamant A, Santoro N. Safety of vaginal estrogens: a systematic review. Menopause. 2020 Mar;27(3):339–360. DOI: 10.1097/GME.0000000000001468
- National Institute for Health and Care Excellence (NICE). Menopause: identification and management [internet]. London: NICE; 2024 Nov 7. (NICE Guideline NG23). Available from:
https://www.nice.org.uk/guidance/ng23 (accessed July 24 2026). - Heo YA. Prasterone: a review in vulvovaginal atrophy. Drugs Aging. 2019 Aug;36(8):781–788. DOI: 10.1007/s40266-019-00693-6
- The NAMS 2020 GSM Position Statement Editorial Panel. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020 Sep;27(9):976–992. DOI: 10.1097/GME.0000000000001609
- SCORE2 Working Group, ESC Cardiovascular Risk Collaboration, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–2454. DOI: 10.1093/eurheartj/ehab309
- Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC
Jr , Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary. J Am Coll Cardiol. 2019;73(24):3168–3209. DOI: 10.1016/j.jacc.2018.11.003 - Cho L, Davis M, Elgendy I, Epps K, Lindley KJ, Mehta PK, Michos ED, Minissian M, Pepine C, Vaccarino V, Volgman AS; ACC CVD Womens Committee Members. Summary of updated recommendations for primary prevention of cardiovascular disease in women: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(20):2602–2618. DOI: 10.1016/j.jacc.2020.03.060
- Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188. DOI: 10.1093/eurheartj/ehz455
- Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016;37(29):2315–2381. DOI: 10.1093/eurheartj/ehw106
- Dzaye O, Dudum R, Reiter-Brennan C, Kianoush S, Tota-Maharaj R, Cainzos-Achirica M, Blaha MJ. Coronary artery calcium scoring for individualized cardiovascular risk estimation in important patient subpopulations after the 2019 AHA/ACC primary prevention guidelines. Prog Cardiovasc Dis. 2019;62(5):423–430. DOI: 10.1016/j.pcad.2019.10.007
- Zoet GA, Benschop L, Boersma E, Budde RPJ, Fauser BCJM, van der Graaf Y, de Groot CJM, Maas AHEM, Roeters van Lennep JE, Steegers EAP, Visseren FL, van Rijn BB, Velthuis BK, Franx A; CREW Consortium. Prevalence of subclinical coronary artery disease assessed by coronary computed tomography angiography in 45- to 55-year-old women with a history of preeclampsia. Circulation. 2018;137(8):877–879. DOI: 10.1161/CIRCULATIONAHA.117.032695
- Gunning MN, Meun C, van Rijn BB, Maas AHEM, Benschop L, Franx A, Boersma E, Budde RPJ, Appelman Y, Lambalk CB, Eijkemans MJC, Velthuis BK, Laven JSE, Fauser BCJM; CREW-consortium. Coronary artery calcification in middle-aged women with premature ovarian insufficiency. Clin Endocrinol (Oxf). 2019;91(2):314–322. DOI: 10.1111/cen.14003
- Chu JH, Michos ED, Ouyang P, Vaidya D, Blumenthal RS, Budoff MJ, Blaha MJ, Whelton SP. Coronary artery calcium and atherosclerotic cardiovascular disease risk in women with early menopause: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Prev Cardiol. 2022;11:100362. DOI: 10.1016/j.ajpc.2022.100362
- Beekman MJ, Terra L, Heemskerk-Gerritsen BAM, van der Aalst CM, Roeters van Lennep JE, van Beurden M, van Doorn HC, de Hullu JA, van Dorst EBL, Mom CH, Mourits MJE, Slangen BFM, Bartels-Rutten A, Budde RPJ, Snoeren MM, Leiner T, de Jong PA, Vliegenthart R, Planken RN, Mihl C, Vonder M, Oudkerk M, Gaarenstroom KN, Gratama JWC, van Engelen K, van der Kolk LE, Collée JM, Wevers MR, Ausems MGEM, Berger LPV, Gomez Garcia EB, van Asperen CJ, Hooning MJ, de Koning HJ, Maas AHEM, van Leeuwen FE. Coronary artery calcium scores after prophylactic premenopausal bilateral salpingo-oophorectomy. JACC CardioOncol. 2024;6(6):922–931. DOI: 10.1016/j.jaccao.2024.09.011
- Gast GC, Grobbee DE, Pop VJ, eyzer JJ, Wijnands-van Gent CJ, Samsioe GN, Nilsson PM, van der Schouw YT. Menopausal complaints are associated with cardiovascular risk factors. Hypertension. 2008;51(6):1492–1498. DOI: 10.1161/HYPERTENSIONAHA.107.106526
- Jackson EA, El Khoudary SR, Crawford SL, Matthews K, Joffe H, Chae C, Thurston RC. Hot flash frequency and blood pressure: data from the Study of Women’s Health Across the Nation. J Womens Health. 2016;25(12):1204–1209. DOI: 10.1089/jwh.2015.5670
- Maas AHEM. Hormone therapy and cardiovascular disease: benefits and harms. Best Pract Res Clin Endocrinol Metab. 2021;35(6):101576. DOI: 10.1016/j.beem.2021.101576
- Vogel B, Acevedo M, Appelman Y, Bairey Merz CN, Chieffo A, Figtree GA, Guerrero M, Kunadian V, Lam CSP, Maas AHEM, Mihailidou AS, Olszanecka A, Poole JE, Saldarriaga C, Saw J, Zühlke L, Mehran R. The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385–2438. DOI: 10.1016/S0140-6736(21)00684-X
- Kunadian V, Chieffo A, Camici PG, Berry C, Escaned J, Maas AHEM, Prescott E, Karam N, Appelman Y, Fraccaro C, Buchanan GL, Manzo-Silberman S, Al-Lamee R, Regar E, Lansky A, Abbott JD, Badimon L, Duncker DJ, Mehran R, Capodanno D, Baumbach A. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation. EuroIntervention. 2021;16(13):1049–1069. DOI: 10.4244/EIJY20M07_01
- Shlipak MG, Angeja BG, Go AS, Frederick PD, Canto JG, Grady D. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation. 2001;104(19):2300–2304. DOI: 10.1161/hc4401.98414
- Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H, McNamee R, Elstein M, Kay C, Seif M, Buckley H; ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360(9350):2001–2008. DOI: 10.1016/S0140-6736(02)12001-0
- Stevenson JC, Collins P, Hodis HN; medical advisory council of the British Menopause Society. Hormone replacement therapy after myocardial infarction: British Menopause Society Tool for Clinicians. Post Reprod Health. 2024;30(2):117–119. DOI: 10.1177/20533691241252300
DOI: https://doi.org/10.5334/gh.1576 | Journal eISSN: 2211-8179
Language: English
Page range: 67 - 67
Submitted on: Jul 15, 2026
Accepted on: Jul 17, 2026
Published on: Sep 22, 2026
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Keywords:
© 2026 Chiara Benedetto, Martha Gulati, Suvarna S. Khadilkar, Angela H. E. M. Maas, Federica Frezet, Gláucia Maria Moraes de Oliveira, Andrea R. Genazzani, Hema Divakar, Athena Poppas, on behalf of the International Federation of Gynecology and Obstetrics (FIGO) and World Heart Federation (WHF), published by Ubiquity Press
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.